Trials / Completed
CompletedNCT00073203
A 6 Week Study to Determine the Effectiveness of R228060 in Adult Subjects With Major Depressive Disorder
A 6- Week, Randomized, Double-Blind, Parallel-Group, Active-and Placebo-Controlled Trial to Assess the Efficacy of R228060 in Adult Subjects With Major Depressive Disorder (MDD)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 488 (planned)
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research study is to determine the effectiveness of 2 target doses of R228060 in comparison with placebo during 6 weeks of treatment in moderately to severely depressed adult subjects with major depressive disorder. Approximately 488 subjects will be involved in the study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | R228060 | |
| DRUG | Placebo and Paroxetine |
Timeline
- Completion
- 2004-05-01
- First posted
- 2003-11-19
- Last updated
- 2009-08-28
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00073203. Inclusion in this directory is not an endorsement.